{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T02:30:39Z","timestamp":1697250639312},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2004,11,1]]},"DOI":"10.1532\/ijh97.04118","type":"journal-article","created":{"date-parts":[[2004,11,30]],"date-time":"2004-11-30T21:11:43Z","timestamp":1101849103000},"page":"306-310","source":"Crossref","is-referenced-by-count":10,"title":["Infectious Risks Associated with the Transfusion of Blood Components and Pathogen Inactivation in Japan"],"prefix":"10.1007","volume":"80","author":[{"given":"Masahiro","family":"Satake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(05)74655-9","author":"Otake, K","year":"2000","unstructured":"Otake K, Nishioka K. Nucleic acid amplification testing of hepatitis B virus. Lancet. 2000;355:1460.","journal-title":"Lancet"},{"key":"E00002","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0166-0934(03)00215-5","volume":"112","author":"Mine, H","year":"2003","unstructured":"Mine H, Emura H, Miyamoto M, et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods. 2003;112:145-151.","journal-title":"J Virol Methods"},{"key":"E00003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1423-0410.2002.tb05316.x","author":"AuBuchon, JP","year":"2002","unstructured":"AuBuchon JP. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine. Vox Sang. 2002;83(suppl 1):271-275.","journal-title":"Vox Sang"},{"key":"E00004","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-12-4443","author":"McCullough, J","year":"2004","unstructured":"McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104:1534-1541.","journal-title":"Blood"},{"key":"E00005","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1046\/j.1537-2995.2001.41121548.x","author":"Atance, R","year":"2001","unstructured":"Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548-1552.","journal-title":"Transfusion"},{"key":"E00006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1423-0410.2002.tb05317.x","author":"Satake, M","year":"2002","unstructured":"Satake M. Residual risk of transfusion-transmitted diseases in Japan and pathogen inactivation. Vox Sang. 2002;83(suppl 1):277-279.","journal-title":"Vox Sang"},{"key":"E00007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1423-0410.2000.7830149.x","volume":"78","author":"Muller-Breitkreutz, K","year":"2000","unstructured":"Muller-Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. Vox Sang. 2000;78:149-157.","journal-title":"Vox Sang"},{"key":"E00008","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","author":"Schreiber, GB","year":"1996","unstructured":"Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections: the Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334:1685-1690.","journal-title":"N Engl J Med"},{"key":"E00009","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1046\/j.1537-2995.2001.41070878.x","author":"Matsumoto, C","year":"2001","unstructured":"Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001;41:878-884.","journal-title":"Transfusion"},{"key":"E00010","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1537-2995.2004.03300.x","volume":"44","author":"Matsubayashi, K","year":"2004","unstructured":"Matsubayashi K, Nagaoka Y, Sakata H, et al.Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004;44:934-940.","journal-title":"Transfusion."},{"key":"E00011","first-page":"376","author":"Wendel, S","year":"2000","unstructured":"Wendel S, Fontao-Wendel R, Germano S, Morato LE, Lazar A, Sakashita A. Screening of bacterial contamination in a routine scale for blood components production in a Brazilian blood bank. Vox Sang. 2000;78(suppl 1):376.","journal-title":"Vox Sang"},{"key":"E00012","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1537-2995.2004.03424.x","author":"Mohr, H","year":"2004","unstructured":"Mohr H, Knuver-Hopf J, Gravemann U, Redecker-Klein A, Muller TH. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion. 2004;44:886-890.","journal-title":"Transfusion"},{"key":"E00013","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1537-2995.2003.00464.x","volume":"43","author":"Mather, T","year":"2003","unstructured":"Mather T, Takeda T, Tassello J, et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion. 2003;43:1029-1037.","journal-title":"Transfusion"},{"key":"E00014","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood.V93.9.3140","author":"Grass, JA","year":"1999","unstructured":"Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140-3147.","journal-title":"Blood"},{"key":"E00015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1704284","author":"Corash, L","year":"2004","unstructured":"Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant. 2004;33:1-7.","journal-title":"Bone Marrow Transplant"},{"key":"E00016","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1191\/096032701718120319","volume":"20","author":"Ciaravino, V","year":"2001","unstructured":"Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (s-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20:533-550.","journal-title":"Hum Exp Toxicol"},{"key":"E00017","first-page":"54","author":"Engelfriet, CP","year":"2003","unstructured":"Engelfriet CP, Reesink HW, Klein HG, et al. The future use of pathogen-inactivated platelet concentrates. Vox Sang. 2003;85:54-66.","journal-title":"Vox Sang"}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.04118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T12:17:32Z","timestamp":1586002652000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.04118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,11,1]]}},"alternative-id":["YM1G087U1U53A2PF"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.04118","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11,1]]}}}